Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs like Zepbound and Wegovy in exchange for tariff relief and wider Medicare access.

The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.

The companies’ medicines will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, a senior administration official said, similar terms to those clinched by their rivals in previous drug-price deals.

“It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americ

See Full Page